Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9Neoplasms 5Prostatic Neoplasms 3Solid Tumors 2Ovarian Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Cancers 1Skin Diseases 1Prostatic Neoplasms, Castration-Resistant 1Neoplasms, Unknown Primary 1Neoplasms by Site 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1Breast Diseases 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

binimetinib 2Watchful Waiting 2Aminolevulinic Acid 2palbociclib 1ipatasertib 1exemestane 1encorafenib 1baricitinib 1atezolizumab 1Vemurafenib 1VP-102 1Trabectedin 1Paclitaxel 1Injections, Intradermal 1Gonadotropin-Releasing Hormone 1Everolimus 1Dacarbazine 1Cantharidin 1BF-200 ALA 1Anastrozole 1AZD9833 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Skin Diseases × ipatasertib × Clear all
NCT04177108 2024-03-27

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Hoffmann-La Roche

Phase 3 Completed
242 enrolled 12 charts
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡